Mutational heterogeneity in cancer and the search for new cancer-associated genes
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reproducibility of scientific findings has been called into question.”
From Evaluating replicability of laboratory experiments in economics (2016) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Melanoma has one of the highest rates of mutation of any cancer16.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [16]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cancer cells are genetically unstable, which contributes to their uncontrolled proliferation and the expression of antigens that can be recognized by the immune system.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“…(GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8 ; MUC4 in melanoma 13 ; olfactory receptor OR2L13 in GBM 14 ; and TTN in breast cancer 12 and other tumor types 15 .”
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationPatterns of somatic mutation in human cancer genomes
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G., Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,080
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“…genes have already cropped up in recently published cancer genome studies, for example: LRP1B in glioblastoma (GBM) 2 and lung adenocarcinoma 1,4 ; CSMD3 in ovarian cancer 2 ; PCLO in diffuse large B-cell lymphoma (DLBCL) 9 ; MUC16 in lung squamous carcinoma 11 , breast cancer 12 and DLBCL 8…”
Self-citationThe Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504 · cited 2×
“Recent studies have also implicated HPV in head-and-neck cancers 5 .”
InfluentialSelf-citationMutational Processes Molding the Genomes of 21 Breast Cancers
Nik-Zainal, S., Alexandrov, L. B., Wedge, D. C., Van Loo, P., Greenman, C. D., Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.024 · Cited by 1,909 · cited 3×
“Recent work 19,20 has shown that the TpC mutations tend to occur in proximity to one another, consistent with the activity of APOBEC enzymes in damaged long single-strand DNA regions.”
Influential
Cited by
Items 401–500 of 1,039
Recurrent somatic mutations in regulatory regions of human cancer genomes
Melton, C., Reuter, J. A., Spacek, D. V., & Snyder, M. (2015) · Nature Genetics · doi:10.1038/ng.3332 · Cited by 236
Systematic Analysis of Splice-Site-Creating Mutations in Cancer
Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N. S., Reynolds, S. M., Zhao, Y., Climente-González, H., Chai, S., Wang, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.052 · Cited by 239
“…Genome Atlas (TCGA) project, haveworked to address the functional consequences of genomic mutations in tumors (Dees et al., 2012; Kandoth et al., 2013; Lawrence et al., 2013; Niu et al., 2016), with the larger goal of determining the underlying mechanisms of cancer initiation and progression.”
Self-citationThe Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Pennock, G. K., & Chow, L. Q. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0422 · Cited by 235
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.008 · Cited by 242
Self-citationDeveloping neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
Human papillomavirus and the landscape of secondary genetic alterations in oral cancers
Gillison, M. L., Akagi, K., Xiao, W., Jiang, B., Pickard, R. K. L., Li, J., Swanson, B. J., Agrawal, A. D., Zucker, M., Stache-Crain, B., et al. (2019) · Genome Research · doi:10.1101/gr.241141.118 · Cited by 236
“Identification of significantly mutated genes To identify significantly mutated genes, MutSigCV 1.4 was run at default settings (Lawrence et al. 2013), using as inputs both variants identified fromWES data sets, downloaded from TCGAwithout modification, and variants called fromWGS data as annotated…”
MethodInfluentialSomatic retrotransposition in human cancer revealed by whole-genome and exome sequencing
Helman, E., Lawrence, M. S., Stewart, C., Sougnez, C., Getz, G., & Meyerson, M. (2014) · Genome Research · doi:10.1101/gr.163659.113 · Cited by 240
Self-citationMechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 240
“The mutation rate of melanoma is among the highest from all cancer types 17 ; however, despite the therapeutic potential of mutated antigens, they are highly patient-specific, and the number of identified shared mutated antigens, derived from recurrent melanoma mutations, remains low 18 .”
BackgroundAAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Chow, R. D., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L., Errami, Y., Dong, M. B., Martinez, M. A., Zhang, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4620 · Cited by 241
Methods of measurement for tumor mutational burden in tumor tissue
Meléndez, B., Van Campenhout, C., Rorive, S., Remmelink, M., Salmon, I., & D’Haene, N. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.08.02 · Cited by 233
The genomic landscape of pediatric cancers: Implications for diagnosis and treatment
Sweet-Cordero, E. A., & Biegel, J. A. (2019) · Science · doi:10.1126/science.aaw3535 · Cited by 225
Self-citationDNA methylation disruption reshapes the hematopoietic differentiation landscape
Izzo, F., Lee, S. C., Poran, A., Chaligne, R., Gaiti, F., Gross, B., Murali, R. R., Deochand, S. D., Ang, C., Jones, P. W., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0595-4 · Cited by 236
Self-citationIntegrative pathway enrichment analysis of multivariate omics data
Paczkowska, M., Barenboim, J., Sintupisut, N., Fox, N. S., Zhu, H., Abd-Rabbo, D., Mee, M. W., Boutros, P. C., PCAWG Drivers and Functional Interpretation Working Group, Abascal, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13983-9 · Cited by 221
“…from the PCAWG project 13 account for confounding factors of somatic mutations, such as gene sequence length and nucleotide content, mutation signatures active in different types of tumors 45 and biological correlates of mutation frequency such as transcription and replication timing 46 .”
BackgroundSelf-citationNovel technologies and emerging biomarkers for personalized cancer immunotherapy
Yuan, J., Hegde, P. S., Clynes, R., Foukas, P. G., Harari, A., Kleen, T. O., Kvistborg, P., Maccalli, C., Maecker, H. T., Page, D. B., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0107-3 · Cited by 229
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, E. J., Bagg, A., Hasserjian, R. P., DiNardo, C. D., Godley, L. A., Iacobucci, I., Jaiswal, S., Malcovati, L., Vannucchi, A. M., Patel, K. P., et al. (2022) · Blood · doi:10.1182/blood.2022015853 · Cited by 217
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S., Perner, J., Bower, L., Devonshire, G., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0331-5 · Cited by 231
Liu, Q., Zhang, J., Guo, C., Wang, M., Wang, C., Yan, Y., Sun, L., Wang, D., Zhang, L., Yu, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.004 · Cited by 207
Self-citationImmunotherapy for Breast Cancer: What Are We Missing?
Vonderheide, R. H., Domchek, S. M., & Clark, A. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2569 · Cited by 233
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 223
Jiang, P., Sun, K., Tong, Y. K., Cheng, S. H., Cheng, T. H. T., Heung, M. M. S., Wong, J., Wong, V. W. S., Chan, H. L. Y., Chan, K. C. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814616115 · Cited by 230
Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30453-x · Cited by 232
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides
McGirt, L. Y., Jia, P., Baerenwald, D. A., Duszynski, R. J., Dahlman, K. B., Zic, J. A., Zwerner, J. P., Hucks, D., Dave, U., Zhao, Z., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611194 · Cited by 232
Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome
Cao, Y., He, M., Gao, Z., Peng, Y., Li, Y., Li, L., Zhou, W., Li, X., Zhong, X., Lei, Y., et al. (2014) · Science · doi:10.1126/science.1249480 · Cited by 232
Zhao, S., Bellone, S., Lopez, S., Thakral, D., Schwab, C., English, D. P., Black, J., Cocco, E., Choi, J., Zammataro, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614120113 · Cited by 228
Chong, W., Shang, L., Liu, J., Fang, Z., Du, F., Wu, H., Liu, Y., Wang, Z., Chen, Y., Jia, S., et al. (2021) · Theranostics · doi:10.7150/thno.52717 · Cited by 229
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
Pietanza, M. C., Byers, L. A., Minna, J. D., & Rudin, C. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2958 · Cited by 228
Genome-driven integrated classification of breast cancer validated in over 7,500 samples
Ali, H. R., Rueda, O. M., Chin, S., Curtis, C. N., Dunning, M., Aparicio, S. A. J. R., & Caldas, C. H. (2014) · Genome biology · doi:10.1186/preaccept-1094756427137059 · Cited by 225
Genomic landscape of high-grade meningiomas
Bi, W. L., Greenwald, N. F., Abedalthagafi, M., Wala, J., Gibson, W. J., Agarwalla, P. K., Horowitz, P., Schumacher, S. E., Esaulova, E., Mei, Y., et al. (2017) · npj Genomic Medicine · doi:10.1038/s41525-017-0014-7 · Cited by 210
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A., Chan-Seng-Yue, M., Wilson, G., Grant, R. C., Merico, D., Lungu, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 231
Spatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 203
Cancer immunotherapy targeting neoantigens
Lu, Y.-C., & Robbins, P. F. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.002 · Cited by 223
Gorris, M. A. J., Halilovic, A., Rabold, K., van Duffelen, A., Wickramasinghe, I. N., Verweij, D., Wortel, I. M. N., Textor, J. C., de Vries, I. J. M., & Figdor, C. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701262 · Cited by 222
Cancer gene mutation frequencies for the U.S. population
Mendiratta, G., Ke, E., Aziz, M., Liarakos, D., Tong, M., & Stites, E. C. (2021) · Nature Communications · doi:10.1038/s41467-021-26213-y · Cited by 208
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Leroy, B., Girard, L., Hollestelle, A., Minna, J. D., Gazdar, A. F., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22556 · Cited by 224
Hovelson, D. H., McDaniel, A. S., Cani, A. K., Johnson, B., Rhodes, K., Williams, P. D., Bandla, S., Bien, G., Choppa, P., Hyland, F., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.03.004 · Cited by 224
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 218
Wang, X., Haswell, J. R., & Roberts, C. W. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0280 · Cited by 222
Self-citationComprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
Moss, T. J., Qi, Y., Xi, L., Peng, B., Kim, T.-B., Ezzedine, N. E., Mosqueda, M. E., Guo, C. C., Czerniak, B. A., Ittmann, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.05.048 · Cited by 226
Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer
Liu, Z., Zhao, Q., Zuo, Z.-X., Yuan, S.-Q., Yu, K., Zhang, Q., Zhang, X., Sheng, H., Ju, H.-Q., Cheng, H., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101302 · Cited by 225
Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma
Lin, D.-C., Mayakonda, A., Dinh, H. Q., Huang, P., Lin, L., Liu, X., Ding, L.-W., Wang, J., Berman, B. P., Song, E.-W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2822 · Cited by 225
Jiao, W., Atwal, G., Polak, P., Karlic, R., Cuppen, E., PCAWG Tumor Subtypes and Clinical Translation Working Group, Al-Shahrour, F., Atwal, G., Bailey, P. J., Biankin, A. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13825-8 · Cited by 217
Self-citationComprehensive assessment of cancer missense mutation clustering in protein structures
Kamburov, A., Lawrence, M. S., Polak, P., Leshchiner, I., Lage, K., Golub, T. R., Lander, E. S., & Getz, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516373112 · Cited by 225
Self-citationLu, X., Jiang, L., Zhang, L., Zhu, Y., Hu, W., Wang, J., Ruan, X., Xu, Z., Meng, X., Gao, J., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.04.003 · Cited by 223
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220
Self-citation3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets
Gao, J., Chang, M. T., Johnsen, H. C., Gao, S. P., Sylvester, B. E., Sumer, S. O., Zhang, H., Solit, D. B., Taylor, B. S., Schultz, N., et al. (2017) · Genome Medicine · doi:10.1186/s13073-016-0393-x · Cited by 217
Integrated genomic analyses of de novo pathways underlying atypical meningiomas
Harmancı, A. S., Youngblood, M. W., Clark, V. E., Coşkun, S., Henegariu, O., Duran, D., Erson-Omay, E. Z., Kaulen, L. D., Lee, T. I., Abraham, B. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14433 · Cited by 213
The Tumor Immune Contexture of Prostate Cancer
Vitkin, N., Nersesian, S., Siemens, D. R., & Koti, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00603 · Cited by 212
Wang, X., Wang, S., Troisi, E. C., Howard, T. P., Haswell, J. R., Wolf, B. K., Hawk, W. H., Ramos, P., Oberlick, E. M., Tzvetkov, E. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09891-7 · Cited by 212
Self-citationPancreatic cancer: optimizing treatment options, new, and emerging targeted therapies
Chiorean, E. G., & Coveler, A. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s60328 · Cited by 215
Davis, R. J., Moore, E. C., Clavijo, P. E., Friedman, J., Cash, H., Chen, Z., Silvin, C., Van Waes, C., & Allen, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2534 · Cited by 213
Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy
Martinez-Bosch, N., Vinaixa, J., & Navarro, P. (2018) · Cancers · doi:10.3390/cancers10010006 · Cited by 209
Keung, E. Z., Burgess, M., Salazar, R., Parra, E. R., Rodrigues-Canales, J., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Attia, S., Riedel, R. F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1824 · Cited by 215
Genomic and Proteomic Resolution of Heterochromatin and Its Restriction of Alternate Fate Genes
Becker, J. S., McCarthy, R. L., Sidoli, S., Donahue, G., Kaeding, K. E., He, Z., Lin, S., Garcia, B. A., & Zaret, K. S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.030 · Cited by 210
“Cancers also have an elevated mutation rate in H3K9me3 domains (Lawrence et al., 2013), which we find to be more pronounced in the srHC and intermediate subtypes compared with euchromatic H3K9me3 (Figure S2E).”
BackgroundDalin, M. G., Desrichard, A., Katabi, N., Makarov, V., Walsh, L. A., Lee, K.-W., Wang, Q., Armenia, J., West, L., Dogan, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0637 · Cited by 214
Eckert, M. A., Pan, S., Hernandez, K. M., Loth, R. M., Andrade, J., Volchenboum, S. L., Faber, P., Montag, A., Lastra, R., Peter, M. E., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0607 · Cited by 216
Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study
Shi, J., Hua, X., Zhu, B., Ravichandran, S., Wang, M., Nguyen, C., Brodie, S. A., Palleschi, A., Alloisio, M., Pariscenti, G., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002162 · Cited by 212
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Marty Pyke, R., Thompson, W. K., Salem, R. M., Font-Burgada, J., Zanetti, M., & Carter, H. (2018) · Cell · doi:10.1016/j.cell.2018.08.048 · Cited by 211
Wang, W., Xu, H., Ye, Q., Tao, F., Wheeldon, I., Yuan, A., Hu, Y., & Wu, J. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00834-6 · Cited by 206
Cancer: Evolution Within a Lifetime
Gerlinger, M., McGranahan, N., Dewhurst, S. M., Burrell, R. A., Tomlinson, I., & Swanton, C. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092314 · Cited by 205
Zhang, X.-C., Wang, J., Shao, G.-G., Wang, Q., Qu, X., Wang, B., Moy, C., Fan, Y., Albertyn, Z., Huang, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09762-1 · Cited by 209
Comprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers
Wang, Z.-L., Li, B., Luo, Y.-X., Lin, Q., Liu, S.-R., Zhang, X.-Q., Zhou, H., Yang, J.-H., & Qu, L.-H. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.035 · Cited by 204
Nava Rodrigues, D., Rescigno, P., Liu, D., Yuan, W., Carreira, S., Lambros, M. B., Seed, G., Mateo, J., Riisnaes, R., Mullane, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121924 · Cited by 203
“org Beyond mutations in canonical MMR genes, we hypothesized that signatures of mutational processes in individual tumors would shed light on DNA repair deficiencies (10, 16, 17) that may associate with distinct immunologic subtypes.”
BackgroundMulti-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas
Castro-Vega, L. J., Letouzé, E., Burnichon, N., Buffet, A., Disderot, P.-H., Khalifa, E., Loriot, C., Elarouci, N., Morin, A., Menara, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms7044 · Cited by 196
“For four patients (18, 25, 42 and 80), we obtained the SNP array profiles of two tumours: coexisting tumours or the primary tumour, and a relapse or metastasis.”
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
Hedberg, M. L., Goh, G., Chiosea, S. I., Bauman, J. E., Freilino, M. L., Zeng, Y., Wang, L., Diergaarde, B. B., Gooding, W. E., Lui, V. W. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82066 · Cited by 200
Adoptive T-Cell Therapy for Cancer
Yang, J. C., & Rosenberg, S. A. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 206
T cell pathology in skin inflammation
Sabat, R., Wolk, K., Loyal, L., Döcke, W.-D., & Ghoreschi, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00742-7 · Cited by 201
“The major base for the strong immunogenicity of melanoma is its often very high (UV-driven) tumor mutational burden, which allows for the creation of neoantigens recognizable as Bnonself^ by host immune cells [152, 153].”
BackgroundZhang, Y., Zuo, C., Liu, L., Hu, Y., Yang, B., Qiu, S., Li, Y., Cao, D., Ju, Z., Ge, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.023 · Cited by 198
Macroscopic somatic clonal expansion in morphologically normal human urothelium
Li, R., Du, Y., Chen, Z., Xu, D., Lin, T., Jin, S., Wang, G., Liu, Z., Lu, M., Chen, X., et al. (2020) · Science · doi:10.1126/science.aba7300 · Cited by 206
The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia
Paulsson, K., Lilljebjörn, H., Biloglav, A., Olsson, L., Rissler, M., Castor, A., Barbany, G., Fogelstrand, L., Nordgren, A., Sjögren, H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3301 · Cited by 198
Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
Tan, D. S. W., Mok, T. S. K., & Rebbeck, T. R. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0096 · Cited by 202
T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 197
CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer
Leiserson, M. D., Wu, H.-T., Vandin, F., & Raphael, B. J. (2015) · Genome Biology · doi:10.1186/s13059-015-0700-7 · Cited by 210
Chromothripsis: A New Mechanism for Rapid Karyotype Evolution
Leibowitz, M. L., Zhang, C.-Z., & Pellman, D. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092228 · Cited by 205
Hayashi, A., Fan, J., Chen, R., Ho, Y.-J., Makohon-Moore, A. P., Lecomte, N., Zhong, Y., Hong, J., Huang, J., Sakamoto, H., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0010-1 · Cited by 203
Brix, N., Tiefenthaller, A., Anders, H., Belka, C., & Lauber, K. (2017) · Immunological Reviews · doi:10.1111/imr.12573 · Cited by 197
A Pharmacogenomic Landscape in Human Liver Cancers
Qiu, Z., Li, H., Zhang, Z., Zhu, Z., He, S., Wang, X., Wang, P., Qin, J., Zhuang, L., Wang, W., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.001 · Cited by 203
ctDNA monitoring using patient-specific sequencing and integration of variant reads
Wan, J. C. M., Heider, K., Gale, D., Murphy, S., Fisher, E., Mouliere, F., Ruiz-Valdepenas, A., Santonja, A., Morris, J., Chandrananda, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8084 · Cited by 194
Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer
Bracken, A. P., Brien, G. L., & Verrijzer, C. P. (2019) · Genes & Development · doi:10.1101/gad.326066.119 · Cited by 192
Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
Grove, C. S., & Vassiliou, G. S. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.015974 · Cited by 172
Heppt, M. V., Heinzerling, L., Kähler, K. C., Forschner, A., Kirchberger, M. C., Loquai, C., Meissner, M., Meier, F., Terheyden, P., Schell, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.038 · Cited by 199
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1467-x · Cited by 201
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
“Despite significant genomic instability, PDA has relatively few coding mutations compared to more immunogenic cancers (Lawrence et al., 2013).”
BackgroundDiscovering and understanding oncogenic gene fusions through data intensive computational approaches
Latysheva, N. S., & Babu, M. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw282 · Cited by 194
Yang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
Predictors of responses to immune checkpoint blockade in advanced melanoma
Jacquelot, N., Roberti, M. P., Enot, D. P., Rusakiewicz, S., Ternès, N., Jegou, S., Woods, D. M., Sodré, A. L., Hansen, M., Meirow, Y., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00608-2 · Cited by 197
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan, Z., Ding, Y., Kim, J., Jung, H. H., Chung, W., Lal, S., Cho, S., Fernandez-Banet, J., Lee, S. K., Kim, S. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04129-4 · Cited by 202
Self-citationImmunogenic cell death in cancer: concept and therapeutic implications
Galluzzi, L., Kepp, O., Hett, E., Kroemer, G., & Marincola, F. M. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04017-6 · Cited by 179
Precision Oncology: The Road Ahead
Senft, D., Leiserson, M. D. M., Ruppin, E., & Ronai, Z. A. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.08.003 · Cited by 195
Tosolini, M., Pont, F., Poupot, M., Vergez, F., Nicolau-Travers, M.-L., Vermijlen, D., Sarry, J. E., Dieli, F., & Fournié, J.-J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284723 · Cited by 191
“48,49 This was illustrated by children ’ s cancers, which typically have few mutations and here presented the least ab TILs whereas cancers associated with durable exposure to carcinogens had the greatest number of these cells (Fig.”
BackgroundAssociation of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer
Li, X., Pasche, B., Zhang, W., & Chen, K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2805 · Cited by 195
The genomic landscape of schwannoma
Agnihotri, S., Jalali, S., Wilson, M. R., Danesh, A., Li, M., Klironomos, G., Krieger, J. R., Mansouri, A., Khan, O., Mamatjan, Y., et al. (2016) · Nature Genetics · doi:10.1038/ng.3688 · Cited by 189
Self-citationChronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis
Parris, B. A., O’Farrell, H. E., Fong, K. M., & Yang, I. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.10.54 · Cited by 194
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192
HLA-Binding Properties of Tumor Neoepitopes in Humans
Fritsch, E. F., Rajasagi, M., Ott, P. A., Brusic, V., Hacohen, N., & Wu, C. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0227 · Cited by 190
Self-citationZhang, W., Mao, J.-H., Zhu, W., Jain, A. K., Liu, K., Brown, J. B., & Karpen, G. H. (2016) · Nature Communications · doi:10.1038/ncomms12619 · Cited by 192
T-cell–based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition
Houot, R., Schultz, L. M., Marabelle, A., & Kohrt, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0190 · Cited by 185
The whole-genome landscape of Burkitt lymphoma subtypes
Panea, R. I., Love, C. L., Shingleton, J. R., Reddy, A., Bailey, J. A., Moormann, A. M., Otieno, J. A., Ong’echa, J. M., Oduor, C. I., Schroeder, K. M. S., et al. (2019) · Blood · doi:10.1182/blood.2019001880 · Cited by 186
APOBEC3A Functions as a Restriction Factor of Human Papillomavirus
Warren, C. J., Xu, T., Guo, K., Griffin, L. M., Westrich, J. A., Lee, D., Lambert, P. F., Santiago, M. L., & Pyeon, D. (2015) · Journal of Virology · doi:10.1128/jvi.02383-14 · Cited by 186
The Genetic Landscape of Diffuse Large B-Cell Lymphoma
Pasqualucci, L., & Dalla-Favera, R. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.01.005 · Cited by 178
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
Self-citation
Metadata
- Authors
- Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., Kiezun, A., Hammerman, P. S., McKenna, A., Drier, Y., Zou, L., Ramos, A. H., Pugh, T. J., Stransky, N., Helman, E., Kim, J., Sougnez, C., Ambrogio, L., Nickerson, E., Shefler, E., Cortés, M. L., Auclair, D., Saksena, G., Voet, D., Noble, M., DiCara, D., Lin, P., Lichtenstein, L., Heiman, D. I., Fennell, T., Imielinski, M., Hernandez, B., Hodis, E., Baca, S., Dulak, A. M., Lohr, J., Landau, D.-A., Wu, C. J., Melendez-Zajgla, J., Hidalgo-Miranda, A., Koren, A., McCarroll, S. A., Mora, J., Lee, R. S., Crompton, B., Onofrio, R., Parkin, M., Winckler, W., Ardlie, K., Gabriel, S. B., Roberts, C. W. M., Biegel, J. A., Stegmaier, K., Bass, A. J., Garraway, L. A., Meyerson, M., Golub, T. R., Gordenin, D. A., Sunyaev, S., Lander, E. S., & Getz, G.
- Affiliations
- Broad Institute (US)
- National Institutes of Health (US)
- Harvard University (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Boston Children's Hospital (US)
- Children's Hospital of Philadelphia (US)
- Corresponding author
- Lander, Eric S.
- Getz, Gad
- ORCID
- Lawrence, Michael S.
- Polak, Paz
- Kryukov, Gregory V.
- Cibulskis, Kristian
- Sivachenko, Andrey
- Carter, Scott L.
- Stewart, Chip
- Mermel, Craig H.
- Roberts, Steven A.
- Hammerman, Peter S.
- McKenna, Aaron
- Drier, Yotam
- Zou, Lihua
- Pugh, Trevor J.
- Stransky, Nicolas
- Helman, Elena
- Kim, Jaegil
- Auclair, Daniel
- Saksena, Gordon
- Noble, Michael
- Lin, Pei
- Heiman, David I.
- Imielinski, Marcin
- Hernandez, Bryan
- Hodis, Eran
- Baca, Sylvan
- Dulak, Austin M.
- Lohr, Jens
- Landau, Dan-Avi
- Wu, Catherine J.
- Koren, Amnon
- McCarroll, Steven A.
- Mora, Jaume
- Crompton, Brian
- Winckler, Wendy
- Ardlie, Kristin
- Gabriel, Stacey B.
- Roberts, Charles W. M.
- Biegel, Jaclyn A.
- Stegmaier, Kimberly
- Bass, Adam J.
- Garraway, Levi A.
- Meyerson, Matthew
- Golub, Todd R.
- Gordenin, Dmitry A.
- Sunyaev, Shamil
- Lander, Eric S.
- Getz, Gad
- Venue
- Nature
- Published
- 2013-06-16
- Volume
- 499
- Issue
- 7457
- Pages
- 214-218
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3919509
- OpenAlex
- W2009720434
- Cited by
- 5,461
- References
- 30
- Citations by year
- 2026: 147 · 2025: 230 · 2024: 288 · 2023: 361 · 2022: 468 · 2021: 580 · 2020: 582 · 2019: 507 · 2018: 537 · 2017: 529 · 2016: 485 · 2015: 396 · 2014: 280 · 2013: 64
- FWCI
- 143.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (U24CA143845, T32CA009216, T32CA009172)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Environmental Health Sciences (Z01ES065073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- mutational heterogeneity, cancer genes, MutSigCV, driver mutations, mutation frequency, lung cancer, lung squamous cell carcinoma, DNA replication timing, transcriptional activity
- MeSH terms
- False Positive Reactions, Humans, Lung Neoplasms, Mutation, Neoplasms, Oncogenes, Reproducibility of Results, Gene Expression, Genome, Human, Artifacts, Neoplasms, Squamous Cell, Sample Size, Genetic Heterogeneity, DNA Replication Timing, Exome, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.